Galectin Therapeutics(GALT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update • NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., August 13, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. Joel Lewis, Chief Executive Officer and President ...